CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Mackensen A, Haanen JB, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, Lüke F, Kutsch N, Müller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, Kühlcke K, Preußner L, Rengstl B, Türeci Ö, Şahin U (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Nature Medicine Nature Publishing Group

DOI: 10.1038/s41591-023-02612-0

Abstract

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and feasibility of chimeric antigen receptor (CAR) T cells targeting the CLDN6 with or without a CAR-T cell-amplifying RNA vaccine (CARVac) at two dose levels (DLs) in relapsed/refractory CLDN6-positive solid tumors. The primary endpoints were safety and tolerability, maximum tolerated dose and recommended phase 2 dose (RP2D). Secondary endpoints included objective response rate (ORR) and disease control rate. We observed manageable toxicity, with 10 out of 22 patients (46%) experiencing cytokine release syndrome including one grade 3 event and 1 out of 22 (5%) with grade 1 immune effector cell-associated neurotoxicity syndrome. Dose-limiting toxicities occurred in two patients at the higher DL, resolving without sequelae. CAR-T cell engraftment was robust, and the addition of CARVac was well tolerated. The unconfirmed ORR in 21 evaluable patients was 33% (7 of 21), including one complete response. The disease control rate was 67% (14 of 21), with stable disease in seven patients. Patients with germ cell tumors treated at the higher DL exhibited the highest response rate (ORR 57% (4 of 7)). The maximum tolerated dose and RP2D were not established as the trial has been amended to utilize an automated manufacturing process. A repeat of the dose escalation is ongoing and will identify a RP2D for pivotal trials. ClinicalTrials.gov Identifier: NCT04503278 .

Authors with CRIS profile

Andreas Mackensen Lehrstuhl für Innere Medizin V Fabian Müller Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Netherlands Cancer Institute (NKI) NL Netherlands (NL) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Bayerisches Zentrum für Krebsforschung (BZKF) DE Germany (DE) Bexon Clinical Consulting US United States (USA) (US) Universitätsklinikum Köln DE Germany (DE) BioNTech / Biopharmaceutical New Technologies DE Germany (DE) BioNTech / Biopharmaceutical New Technologies US United States (USA) (US)

How to cite

APA:

Mackensen, A., Haanen, J.B., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Borchmann, P.,... Şahin, U. (2023). CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02612-0

MLA:

Mackensen, Andreas, et al. "CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial." Nature Medicine (2023).

BibTeX: Download